NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Medical University of Graz